Clinical Trials

Amgen’s Dazodalibep Meets Primary Goal in Phase 3 Sjögren’s Trial

The topline result raises the prospect of the first FDA‑approved therapy for Sjögren’s disease, with full data and a second Phase 3 readout determining approval chances.